BRPI0908221A2 - processo para preparar uma formulação farmacêutica de agentes de contraste - Google Patents

processo para preparar uma formulação farmacêutica de agentes de contraste

Info

Publication number
BRPI0908221A2
BRPI0908221A2 BRPI0908221-2A BRPI0908221A BRPI0908221A2 BR PI0908221 A2 BRPI0908221 A2 BR PI0908221A2 BR PI0908221 A BRPI0908221 A BR PI0908221A BR PI0908221 A2 BRPI0908221 A2 BR PI0908221A2
Authority
BR
Brazil
Prior art keywords
preparing
pharmaceutical formulation
contrast agents
agents
contrast
Prior art date
Application number
BRPI0908221-2A
Other languages
English (en)
Inventor
Meyer Dominique
Corot Claire
Port Marc
Barbotin Vincent
Bonnemain Bruno
Original Assignee
Guerbet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40955314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908221(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0851055A external-priority patent/FR2927539B1/fr
Application filed by Guerbet filed Critical Guerbet
Publication of BRPI0908221A2 publication Critical patent/BRPI0908221A2/pt
Publication of BRPI0908221B1 publication Critical patent/BRPI0908221B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0908221-2A 2008-02-19 2009-02-18 Processo para preparar uma formulação farmacêutica líquida contendo um complexo de quelate macrocíclico com um lantanídeo BRPI0908221B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FR0851055 2008-02-19
FR0851055A FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
EP08154745 2008-04-17
EP08154745.7 2008-04-17
US12/155,997 US20090208421A1 (en) 2008-02-19 2008-06-12 Process for preparing a pharmaceutical formulation of contrast agents
US12/155,997 2008-06-12
PCT/EP2009/051937 WO2009103744A2 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents

Publications (2)

Publication Number Publication Date
BRPI0908221A2 true BRPI0908221A2 (pt) 2018-03-20
BRPI0908221B1 BRPI0908221B1 (pt) 2021-07-13

Family

ID=40955314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908221-2A BRPI0908221B1 (pt) 2008-02-19 2009-02-18 Processo para preparar uma formulação farmacêutica líquida contendo um complexo de quelate macrocíclico com um lantanídeo

Country Status (17)

Country Link
US (6) US20090208421A1 (pt)
EP (6) EP2799089B9 (pt)
JP (3) JP5469615B2 (pt)
KR (1) KR101063060B1 (pt)
CN (1) CN101977633B (pt)
BR (1) BRPI0908221B1 (pt)
CA (1) CA2714118C (pt)
CY (2) CY1115259T1 (pt)
DE (1) DE202008010019U1 (pt)
DK (3) DK2799090T4 (pt)
ES (3) ES2597782T3 (pt)
HR (2) HRP20140537T1 (pt)
HU (2) HUE030219T2 (pt)
LT (2) LT2799089T (pt)
PL (3) PL2799090T5 (pt)
PT (3) PT2799090T (pt)
WO (1) WO2009103744A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) * 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) * 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
DK2941233T3 (da) * 2013-01-07 2020-10-19 Univ Pennsylvania Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
EP2786768A1 (en) * 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
HRP20170874T4 (hr) 2013-04-26 2022-09-02 Guerbet Formulacija kontrastnog medija i odgovarajući postupak dobivanja
KR101466602B1 (ko) * 2013-05-31 2014-12-01 동국제약 주식회사 메글루민 가도테레이트를 포함하는 조영제 조성물의 제조방법
AT516104B1 (de) * 2014-07-31 2016-08-15 Sanochemia Pharmazeutika Ag Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung
KR101646211B1 (ko) * 2014-11-12 2016-08-05 (주)디아이테크 자기공명영상용 조영제의 제조방법
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
GB201421162D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
GB201421163D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Formulations of metal complexes
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20170035461A1 (en) * 2015-08-03 2017-02-09 Jeffery Deal Reversible tattoo colorant and method
DE102015013939A1 (de) * 2015-09-15 2017-03-16 be imaging GmbH Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen
EP3183009B1 (en) * 2015-09-30 2023-08-09 Duke University Contrast agents for magnetic resonance imaging
KR101625656B1 (ko) * 2015-10-16 2016-05-30 최경석 자기공명영상용 조영제의 제조방법
EP3383441A1 (en) * 2015-11-30 2018-10-10 GE Healthcare AS Formulations comprising a combination of mri contrast agents
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
EP3315141B1 (de) * 2016-10-28 2020-10-21 B.E. Imaging GmbH Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
JP7258753B2 (ja) 2016-12-21 2023-04-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ Ｍｒｉイメージング剤として好適なテトラアザビシクロ大員環系マンガンキレート化合物
EP3562517A1 (en) * 2016-12-29 2019-11-06 Inventure, LLC Solvent-free gadolinium contrast agents
US20190269805A1 (en) * 2016-12-29 2019-09-05 Inventure, LLC Solvent-free gadolinium contrast agents
WO2018204869A1 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3638320A4 (en) 2017-05-05 2021-01-20 Centre for Probe Development and Commercialization IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
WO2019020662A1 (de) * 2017-07-27 2019-01-31 Sanochemia Pharmazeutika Ag Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen
FR3072281B1 (fr) * 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
US11110186B2 (en) 2017-12-20 2021-09-07 General Electric Company Anionic chelate compounds
AT521001B1 (de) 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
EP3883613A1 (en) * 2018-11-23 2021-09-29 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
JP2022517193A (ja) * 2019-01-03 2022-03-07 アイオンパス， インク． イオンビームイメージングのための組成物および試薬
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
AU2020291197A1 (en) * 2019-06-14 2022-01-27 Edinburgh Molecular Imaging Limited Compounds and methods of use
US20220370646A1 (en) * 2019-10-25 2022-11-24 Bracco Imaging S.P.A. Pharmaceutical compositions of gd-based contrast agents
GB201919073D0 (en) 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
TWI779284B (zh) * 2020-05-06 2022-10-01 商之器科技股份有限公司 用於影像資料標註的裝置
CN115916761B (zh) 2020-06-10 2025-08-12 贾斯特萨影象独资有限公司 利用高纯度四西坦(dota)制取钆特酸葡甲胺的方法及其在制备可注射盖仑制剂中的应用
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法
WO2025034668A1 (en) * 2023-08-04 2025-02-13 Inventure, LLC Lanthanide-based contrast agents having improved stability and methods for their production and purification
CN119612783B (zh) * 2024-12-23 2025-09-02 欣格瑞(山东)化学有限公司 一种硫酸钡锶除垢剂的制备方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4639365A (en) 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US5082649A (en) 1987-06-30 1992-01-21 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5049667A (en) 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
EP0367787B2 (en) 1987-06-30 1999-01-27 Mallinckrodt, Inc. (a Delaware corporation) Method for enhancing the safety of metal-ligand chelates as x-ray contrast agents
NZ230778A (en) 1988-09-27 1993-01-27 Salutar Inc Diagnostic imaging contrast medium comprising biscarbamoyl derivatives
JPH02173483A (ja) 1988-12-23 1990-07-04 Komatsu Ltd 高速流量制御弁
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US4967447A (en) 1989-09-25 1990-11-06 Romaine Jeffrey L Fish slicer and method of frying fish
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9000564D0 (en) 1990-01-10 1990-03-14 Dow Rheinmuenster Modified polyoxyethlene epoxy resin amphiphiles and stable aqueous epoxy dispersions thereof
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US7385041B2 (en) * 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
JPH07505886A (ja) * 1992-04-13 1995-06-29 ザ　ダウ　ケミカル　カンパニー マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
FR2736051B3 (fr) * 1995-06-29 1997-09-26 Guerbet Sa Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US7048907B2 (en) * 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
AU2003261398A1 (en) * 2002-08-06 2004-02-23 Epix Pharmaceuticals, Inc. Peptide aggregates
WO2007002109A2 (en) 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
JP2009530294A (ja) 2006-03-15 2009-08-27 マリンクロット インコーポレイテッド 置換芳香族部分を有するキレート化接合体およびその誘導体
WO2007121453A2 (en) 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents

Also Published As

Publication number Publication date
DE202008010019U1 (de) 2009-07-02
PL2242515T3 (pl) 2014-08-29
ES2593127T9 (es) 2017-05-08
US9636427B2 (en) 2017-05-02
EP2799090B9 (en) 2016-12-21
JP2014114306A (ja) 2014-06-26
HRP20161312T1 (hr) 2016-12-16
US9907866B2 (en) 2018-03-06
PT2799089T (pt) 2016-10-25
ES2593127T5 (es) 2020-09-25
DK2799090T5 (en) 2017-04-18
EP2799089B9 (en) 2017-09-06
LT2799089T (lt) 2016-11-10
US20130336898A1 (en) 2013-12-19
CY1115259T1 (el) 2017-01-04
US20090208421A1 (en) 2009-08-20
US20110129425A1 (en) 2011-06-02
EP3620179A1 (en) 2020-03-11
DK2799089T3 (en) 2016-11-21
CY1118985T1 (el) 2018-01-10
JP6422460B2 (ja) 2018-11-14
CA2714118C (en) 2017-03-28
EP2799090B1 (en) 2016-06-29
HRP20161312T2 (hr) 2018-01-26
DK2799090T4 (da) 2020-05-18
JP5985523B2 (ja) 2016-09-06
ES2477541T3 (es) 2014-07-17
PL2799089T3 (pl) 2017-08-31
BRPI0908221B1 (pt) 2021-07-13
EP3159014A1 (en) 2017-04-26
EP2799090A2 (en) 2014-11-05
LT2799090T (lt) 2016-10-10
HUE030219T2 (en) 2017-04-28
EP2799090A3 (en) 2015-01-14
EP2242515B9 (en) 2014-10-01
KR101063060B1 (ko) 2011-09-07
EP2799089A3 (en) 2015-03-04
JP2016117778A (ja) 2016-06-30
HRP20140537T1 (hr) 2014-07-18
PT2799090T (pt) 2016-09-28
PT2242515E (pt) 2014-07-11
US20160235867A1 (en) 2016-08-18
JP2011514334A (ja) 2011-05-06
EP2799089B1 (en) 2016-08-03
PL2799090T5 (pl) 2020-07-13
EP2799089A2 (en) 2014-11-05
WO2009103744A2 (en) 2009-08-27
PL2799090T3 (pl) 2017-08-31
KR20100133976A (ko) 2010-12-22
WO2009103744A3 (en) 2009-12-17
HUE031091T2 (en) 2017-06-28
US9655983B2 (en) 2017-05-23
EP2242515A2 (en) 2010-10-27
ES2597782T3 (es) 2017-01-23
ES2593127T3 (es) 2016-12-05
EP2799090B2 (en) 2020-03-04
DK2242515T3 (da) 2014-07-07
CN101977633B (zh) 2012-08-29
DK2799090T3 (en) 2016-10-03
US20170189563A1 (en) 2017-07-06
JP5469615B2 (ja) 2014-04-16
CA2714118A1 (en) 2009-08-27
EP2591807A1 (en) 2013-05-15
EP2242515B1 (en) 2014-04-02
CN101977633A (zh) 2011-02-16
US20160235868A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
BRPI0908221A2 (pt) processo para preparar uma formulação farmacêutica de agentes de contraste
BR112013013042A2 (pt) processo para preparação de uma formulação farmacêutica contendo ppi
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
BRPI1013561A8 (pt) processo para a preparação de alogliptina
BRPI0911254A2 (pt) processo para a preparação de um composto
BRPI0916609A2 (pt) Processo para a preparação de um macrociclo
BRPI0916712A2 (pt) processo para preparar uma composição detergente
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
BRPI0909655A2 (pt) Processo para a preparação regioseletiva de derivados de ácido 1-alquil-3-haloalquil-pirazol-4carboxílico
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0817747A2 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
BRPI0914118A2 (pt) processo para preparação de látex artificial
BRPI0909393A2 (pt) processo para a preparação de polibutadieno
BRPI1010707A2 (pt) composição farmacêutica, processo para o preparo da mesma, processo para o preparo de uma formulação injetável e formulação injetável
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
BRPI1007654A2 (pt) composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
BRPI0918685A2 (pt) formulação tópica e processo de preparação de uma formulação tópica
BR112012002500A2 (pt) Processo para o preparo de derivados de ácido 1- (2-halobifenil-4-yl) - ciclopropanocarboxílico
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo
BR112013022930A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica
BR112012001731A2 (pt) Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol
BRPI0920071A2 (pt) Processo para a preparacao de produtos de chocolate com recheio

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.5 NA RPI NO 2482 DE 31/07/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.